Could a diabetes drug prevent heart failure in people with high blood pressure?
NCT ID NCT06055452
First seen Mar 06, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This study tests whether a drug called engagliflozin (an SGLT2 inhibitor) can improve heart function in people with pre-heart failure and high blood pressure who do not have diabetes. About 120 participants will receive either the drug or a placebo for 6 months. The main goal is to see if the drug reduces the size of the heart's left atrium, which is a sign of better heart function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital Chinese Academy of Medial Sciences, Shenzhen
RECRUITINGShenzhen, Guangdong, 518038, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.